Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you've had a gastric bypass and your weight has started to creep back up, you may be wondering whether GLP-1 weight loss injections could help. The honest answer is: possibly, but the picture is more complicated than for someone who hasn't had bariatric surgery. Anatomy changes, absorption differences and clinical safety considerations all need careful prescriber review before any injection treatment begins. These are prescription-only medicines, and a clinician assesses every case individually.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Gastric bypass is one of the most effective weight-loss interventions available, but weight regain happens, and it is far more common than surgical teams or patients expect. Studies consistently show that a meaningful proportion of people regain a significant portion of lost weight within five to ten years, driven by hormonal adaptation, changes in appetite signalling over time and the ordinary pressures of life. If you are reading this page, you probably already know that story from the inside.
The question of whether weight loss injections can help at this stage is a reasonable one. GLP-1 receptor agonists work on the appetite-regulating pathways in the brain and gut, slowing gastric emptying and reducing hunger signals. In that sense, their mechanism does not depend on having an intact stomach. But a bypass creates a new anatomy, and that changes several practical considerations worth understanding before you speak to a prescriber.
Interestingly, some research suggests that GLP-1 hormone secretion actually rises after gastric bypass, which is part of why the surgery works so well initially. Using a GLP-1 medicine on top of that elevated baseline is one of the things a clinician needs to think through with you.
The licensed eligibility criteria for tirzepatide (Mounjaro) and semaglutide (Wegovy) centre on BMI and the presence of weight-related health conditions, you can read the full eligibility framework on the weight loss treatment overview. Many people who have regained weight after a bypass still meet those thresholds numerically. Meeting the numbers, though, is just the start of the assessment.
A thorough prescriber will want to know your current nutritional status. Bypass surgery already puts patients at risk of deficiencies in B12, iron, calcium and vitamin D. GLP-1 medicines reduce appetite and food intake further, which can compound that risk if supplementation is not already solid. The connection between B12 and weight management is worth understanding separately, but the short version is: nutritional monitoring becomes even more important on injection treatment after any bariatric procedure.
GI side effects (nausea, loose stools, vomiting) are the most commonly reported effects of GLP-1 medicines in the general population. After a bypass, the altered gut anatomy and faster intestinal transit can mean these effects feel sharper, at least in the early weeks. Starting at the lowest dose and moving slowly through the titration schedule is standard practice; after bypass, there is even less reason to rush that process. Weight loss injections after bariatric surgery more broadly carries further detail on how different procedures affect this picture.
The NHS's guidance on weight-management injections notes that patients should tell their healthcare team about any previous GI surgery before starting treatment, and this is precisely the kind of history that shapes a responsible clinical decision.
Gastric bypass (Roux-en-Y) and gastric sleeve are different operations with different physiological consequences. Both reduce stomach capacity, but bypass reroutes the small intestine as well, which is why absorption differences are more pronounced. If you have had a sleeve rather than a bypass, the considerations overlap but are not identical, there is a separate page covering weight loss injections after gastric sleeve surgery that is worth reading.
For bypass patients specifically, the rerouted intestine affects how some oral medicines are absorbed, less so for subcutaneous injections, which go directly into the tissue beneath the skin and bypass the gut entirely. That is one reason why injectable GLP-1 treatments are generally considered more predictable in this context than oral formulations. The prescriber will still want to review any other medicines you take, as interactions and absorption changes can ripple outward.
None of this means injection treatment is off the table. It means the consultation needs to be more detailed, not less. A prescriber who reviews your case quickly without asking about surgical history, current supplementation or any ongoing GI symptoms is not doing the job properly. At nume, every consultation is read personally by a GPhC-registered prescriber, not processed by an algorithm.
If you are wondering what results look like for people in this situation specifically, the evidence base is thinner than for the general population, most large trials excluded post-bariatric patients. What the data does show is that GLP-1 medicines produce meaningful weight reduction in a broad range of adults with obesity. The SURMOUNT-1 trial, for instance, recorded average weight reductions of around 20% over 72 weeks at the highest tirzepatide dose, as published in the New England Journal of Medicine. Whether that translates directly to someone who has already had a bypass is genuinely unclear, and any prescriber who tells you otherwise is overstating the evidence.
What is realistic to say is that weight regain after bypass is a recognised medical problem, not a personal failing, and that pharmacological support is an established part of the clinical toolkit for managing it. For many people, the injection pens arrive the next working day after approval (plain packaging, tracked by DPD, nothing on the outside to suggest what's inside) and the treatment begins alongside the lifestyle work that makes it stick.
Before you look at pricing, which varies by medicine and dose, the most useful step is understanding whether you are clinically suitable. You can find a broader comparison of what injection treatment looks like in practice, and if you want to understand the cost landscape honestly, the weight loss injection cost guide sets out what legitimate private treatment involves. The NHS guidance on weight-management injections is also worth a read for background on how clinical decisions are framed.
If you've had a gastric bypass, regained weight and want a prescriber to look at your situation properly, start your free consultation and give the full surgical history in your answers. That detail is exactly what the review is for.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.